Loading…
← CockpitCompetitor Analysis › SOON.SW Sonova Holding AGOpen in the cockpit ↗

Sonova Holding AGSOON.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Medical Specialties

World's largest hearing-aid maker, also selling cochlear implants (Advanced Bionics) and audiological equipment.

≈ A much larger version of Eargo, the US hearing-aid companyMomentum leader 94
Mkt cap
$19.8B
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$54.6M
20-day average traded
Fwd P/E
25.3×
forward earnings
ROIC−WACC
+11.0 pp
WACC 6.0%
Hurdle
-1 pp
Req g minus delivered
Next earnings
181 days
18 May 2027
Close · CHFCHF 290.60
1D+1.0%
1W+2.8%
1M+4.3%
3M+19.0%
6M+39.9%
YTD+40.3%
1Y+43.4%
ATR %2.4%
52w lowhigh1.6% off high

What Sonova does

World's largest hearing-aid maker, also selling cochlear implants (Advanced Bionics) and audiological equipment.

Sells hearing aids both to independent audiologists and hearing-care chains and through its own retail clinics (AudioNova), which keeps more of the margin per device; hearing aids, led by the Phonak brand, carry most of the business. Cochlear implants through Advanced Bionics are a smaller business.

In one line: A much larger version of Eargo, the US hearing-aid company.

Products and services

  • Hearing aids (Phonak, Unitron)
  • Cochlear implants (Advanced Bionics)
  • Audiological/diagnostic equipment
  • Retail hearing-care clinics

Customers

  • Audiologists
  • Hearing-care retail chains
  • Patients with hearing loss

Where it sits in the supply chain

  • Health care
  • Hearing health
  • Hearing aids & cochlear implants

What could go right

  • Aging population/rising hearing-loss diagnosis
  • OTC hearing-aid category growth in the US

What could go wrong

  • OTC/lower-price competition
  • Retail-clinic reimbursement pressure

Moat: narrow (brand, distribution, switching costs). Audiologist relationships, owned retail clinics and R&D scale support share as hearing-loss diagnosis rises.

Headquarters: Stäfa, Switzerland · Founded: 1947 · Employees: 18,447

Named competitors

Sonova at a glance

Size Sonova (SOON.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $19.8B, the 26th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 290.60 on 18 Nov 2026.

Performance Over six months the shares gained 39.9%, against +25.9% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue fell 5.8% over the last twelve months (peer median +7.6%); the operating margin is 22.7% (peer median 17.0%).

Valuation It trades at 25.3× forward earnings against a peer median of 28.0× (8th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 11.0 points above its cost of capital (6.0% WACC).

Next results Next results expected around 18 May 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026SOON.SW 138Peer median 124
Six months, rebased to 100: Sonova against the median of its 20 peers (local-currency closes).

Sonova financials

Reported figures in CHF; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 3.62BCHF 3.61BCHF 3.61BCHF 3.63BCHF 3.74B
Revenue growth—0%0%-3%—
Gross profitCHF 2.72BCHF 2.60BCHF 2.63BCHF 2.56BCHF 2.59B
EBITDACHF 1.06BCHF 968MCHF 1.03BCHF 940MCHF 1.00B
Net incomeCHF 493MCHF 431MCHF 540MCHF 601MCHF 648M
Free cash flowCHF 695MCHF 603MCHF 688MCHF 646MCHF 666M
Capital expenditureCHF 116MCHF 103MCHF 132MCHF 129MCHF 154M
Total debtn/aCHF 1.71BCHF 1.76BCHF 1.79BCHF 1.81B

Quarterly statements and history in the cockpit →

Sonova competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%SRTGHZBHSTMNRVTYCOLO-B4543DIMSTE688271WSTGKOSLENSKARTBAXDXCM7733PENSNILMNBIMSOON.SW6-month return →1-month return →
Up and to the right = strong over both horizons. Sonova is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×50×100×150×SRTZBHSTMNRVTYCOLO-B4543688271WSTGKOSLENSKARTBAXDXCMPENBIMSOON.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sonova is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%SRTZBHSTMNRVTYCOLO-B4543DIMWSTLENSKARTBAXDXCM7733PENSNBIMSOON.SWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sonova is the large dot.

Sonova competitors and peer comparison

Head to head with its named competitors (SOON.SW vs DEMANT.CO vs GN.CO vs COH.AX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sonova SOON.SW$19.8B+40%-6%23%25.3×6.0%
Demant A/S DEMANT.CO$10.4B+39%+10%18%23.2×5.8%
GN Store Nord A/S GN.CO$2.52B+25%-35%3%n/a20.7%
Cochlear COH.AX$6.72B+58%-1%13%29.1×23.9%

How Sonova compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sonova against its 20 peers (data as of 18 Nov 2026)
MeasureSOON.SWPeer medianRank in peer set
1-month return+4.3%+5.7%8th lowest of 21
6-month return+39.9%+25.9%5th highest of 21
Distance from 52-week high-1.6%-11.1%2nd highest of 21
Revenue growth (TTM)-5.8%+7.6%lowest of 21
Operating margin22.7%17.0%4th highest of 21
Forward P/E25.3×28.0×8th cheapest of 20
Growth the price implies (Req g, 7 yrs)6.0%16.2%3rd least demanding of 18
Growth delivered (Del g)+6.7%+8.3%8th lowest of 18
Hurdle (Req g minus delivered)-0.8 pp+5.5 pp4th least demanding of 18
ROIC minus cost of capital+11.0 pp+1.9 pp6th highest of 21
EV / EBITDA16.7×20.2×9th cheapest of 18
Net debt / EBITDA1.0×0.8×8th most indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sonova SOON.SWSwitzerland$19.8B+40%-6%23%25.3×6.0%+6.7%
Sartorius SRT.DEGermany$19.9B+26%+4%18%43.0×25.6%+8.7%
Guardant Health GHUnited States$19.6B+26%+42%-39%n/an/an/a
Zimmer Biomet ZBHUnited States$19.6B+21%+7%16%11.7×7.4%+3.2%
Straumann STMN.SWSwitzerland$20.4B+20%+2%21%32.9×16.2%+12.8%
Revvity RVTYUnited States$17.0B+61%+5%16%26.2×26.4%-5.5%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%20.0×-2.1%+8.3%
Terumo 4543.TJapan$24.0B+32%+15%17%27.8×8.8%+13.0%
Sartorius Stedim Biotech DIM.PAFrance$24.2B+32%+4%19%45.7×33.4%+9.2%
Steris STEUnited States$25.2B+21%+8%20%21.9×14.0%+13.8%
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%45.7×n/an/a
West Pharmaceutical Services WSTUnited States$28.1B+32%+13%23%40.2×25.8%+7.4%
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
Dexcom DXCMUnited States$30.8B+16%+13%24%28.0×19.6%+19.3%
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Illumina ILMNUnited States$31.8B+48%+6%21%35.2×27.2%+6.0%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%

Questions

Who are Sonova's main competitors?
Named competitors: Demant (DEMANT.CO), GN Store Nord (GN.CO), WS Audiology (private or unlisted), Cochlear Limited (COH.AX), Starkey (private or unlisted). The cockpit's measured peer set (industry) also includes Sartorius (SRT.DE), Guardant Health (GH), Zimmer Biomet (ZBH), Straumann (STMN.SW), Revvity (RVTY), Coloplast A/S (COLO-B.CO).
Is Sonova expensive compared with its peers?
On forward p/e it trades at 25.3× against a peer median of 28.0×, 8th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Sonova stock performed?
Over six months to 18 Nov 2026 the shares returned +39.9% against +25.9% for the median peer; over one year +43.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.